论文部分内容阅读
迄今,已有两篇关于~(99m)锝(~(99m)Tc)标记抗体用于临床检测肿瘤的报道。最早是在加拿大温哥华总医院,由RobertMorrison指导进行。最近,意大利在国家研究委员会的赞助下由A G Siccardi协调进行了多中心临床试验。首次临床试验用抗HCG-β单克隆抗体的F(ab′)_2片段于51例病人,其中53％呈现可见的病灶。
So far, there have been two reports on ~(99m)锝 (~(99m)Tc) labeled antibodies for clinical detection of tumors. The earliest was at Vancouver General Hospital in Canada, under the guidance of Robert Morrison. Recently, Italy coordinated multi-center clinical trials by A G Siccardi under the auspices of the National Research Council. In the first clinical trial, F(ab′)_2 fragment of anti-HCG-β monoclonal antibody was used in 51 patients, of which 53% showed visible lesions.